Depression is one of the major healthcare burdens worldwide leading to lower productivity and in severe cases leading to suicidal tendencies. Anti-depressant and anti-psychotic drugs are especially high in demand during economic crisis and social negligence. These drugs also serve as a therapy for preventing suicidal thoughts and attempts. However, overdose of these drugs can be fatal and therefore, needs to be administered under the direction of a physician.

The global Anti-Suicide Drugs market was valued at 3600 million US$ in 2018 and will reach 5210 million US$ by the end of 2025, growing at a CAGR of 4.7% during 2019-2025.
This report focuses on Anti-Suicide Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Anti-Suicide Drugs market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Anti-Suicide Drugs in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Anti-Suicide Drugs manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Pfizer
AstraZeneca plc
Eli Lilly and Company
Allergan plc
GlaxoSmithKline plc
Merck & Co., Inc
H. Lundbeck A/S
NeuroRx, Inc
Johnson & Johnson

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Anti-Depressants and Anti-Anxiety Drugs
Anti-Psychotic Drugs
NMDA Antagonist
Antibiotic Analog

Segment by Application
Hospitals
Retail pharmacies
Online pharmacies